Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.2% on Friday.

Shares of NIKE, Inc. (NYSE:NKE) fell sharply in today's pre-market trading following fourth-quarter earnings and soft FY25 guidance.

Analysts at Stifel and Morgan Stanley downgraded the stock following the report.

NIKE shares dipped 15.6% to $79.42 in pre-market trading.

Here are some big stocks recording losses in today's pre-market trading session.

• Accolade, Inc. (NASDAQ:ACCD) shares tumbled 32.1% to $4.34 in pre-market trading after the company reported first-quarter financial results and issued worse-than-expected FY25 revenue guidance. Also, Needham maintained a Buy rating on the stock but lowered its price target from $13 to $8.
• PTC Therapeutics, Inc. (NASDAQ:PTCT) shares slipped 13.5% to $30.00 in pre-market trading after the company said CHMP has issued negative opinion on renewal of conditional marketing authorization of Translarna (Ataluren) for the treatment of nmDMD.
• Kura Sushi USA, Inc. (NASDAQ:KRUS) shares declined 12.4% to $72.00 in pre-market trading after the company issued soft guidance.
• Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) shares fell 12.4% to $18.75 in pre-market trading. The company announced the FDA issued a Complete Response Letter for the License Application For KRESLADI and requested limited additional Chemistry Manufacturing and Controls information to complete its review.
• Polestar Automotive Holding UK PLC (NASDAQ:PSNY) fell 7.7% to $0.7613 in pre-market trading after the company published full year 2023 results.
• Foot Locker, Inc. (NYSE:FL) shares fell 5.3% to $24.16 in pre-market trading.
• Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares declined 4.1% to $39.84 in pre-market trading. Apellis plans to seek re-examination following negative CHMP opinion for pegcetacoplan for geographic atrophy (GA) in the EU.

Now Read This: IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying

Don't forget to check out our premarket coverage here